{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan Y"],"funding":["Science and Technology Commission of Shanghai Municipality","Chinese Academy of Medical Sciences","National Natural Science Foundation of China","National Cancer Institute","American Lebanese Syrian Associated Charities","NCI NIH HHS","Innovationsfonden","National Institutes of Health","Children's Cancer Foundation"],"pagination":["587-596"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9649883"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["199(4)"],"pubmed_abstract":["The effect of prolonged pulse therapy with vincristine and dexamethasone (VD) during maintenance therapy on the outcome of paediatric patients with TCF3-PBX1 positive acute lymphoblastic leukaemia (ALL) remains uncertain. We conducted non-inferiority analysis of 263 newly diagnosed TCF3-PBX1 positive ALL children who were stratified and randomly assigned (1:1) to receive seven additional VD pulses (the control group) or not (the experimental group) in the CCCG-ALL-2015 clinical trial from January 2015 to December 2019 (ChiCTR-IPR-14005706). There was no significant difference in baseline characteristics between the two groups. With a median follow-up of 4.2 years, the 5-year event-free survival (EFS) and 5-year overall survival (OS) in the control group were 90.1% (95% confidence interval "],"journal":["British journal of haematology"],"pubmed_title":["Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia."],"pmcid":["PMC9649883"],"funding_grant_id":["P30 CA021765","(81670136) (JCa)","(21Y31900302) (XWZ)","(82141125) (XWZ)","(81870131) (XFZ)"],"pubmed_authors":["Ju X","Hu S","Pui CH","Zhang H","Jiang H","Cai J","Gao J","Wan Y","Zhang L","Yu J","Wang J","Liang C","Sun L","Wang N","Tang J","Li CK","Zhai X","Shen S","Wu X","Li H","Yang J","Jin R","Yang M","Fang Y","Tian X","Leung AWK","Zhu X","Hu Q"],"additional_accession":[]},"is_claimable":false,"name":"Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.","description":"The effect of prolonged pulse therapy with vincristine and dexamethasone (VD) during maintenance therapy on the outcome of paediatric patients with TCF3-PBX1 positive acute lymphoblastic leukaemia (ALL) remains uncertain. We conducted non-inferiority analysis of 263 newly diagnosed TCF3-PBX1 positive ALL children who were stratified and randomly assigned (1:1) to receive seven additional VD pulses (the control group) or not (the experimental group) in the CCCG-ALL-2015 clinical trial from January 2015 to December 2019 (ChiCTR-IPR-14005706). There was no significant difference in baseline characteristics between the two groups. With a median follow-up of 4.2 years, the 5-year event-free survival (EFS) and 5-year overall survival (OS) in the control group were 90.1% (95% confidence interval ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T22:50:42.999Z","creation":"2025-04-04T22:50:42.999Z"},"accession":"S-EPMC9649883","cross_references":{"pubmed":["36114009"],"doi":["10.1111/bjh.18437"]}}